Neurodevelopmental Outcomes in Preterm Infants with Retinopathy of Prematurity

Over the past decade there has been a paradigm shift in the treatment of retinopathy of prematurity (ROP) with the introduction of anti-vascular endothelial growth factor (anti-VEGF) treatments. Anti-VEGF agents have the advantages of being easier to administer, requiring less anesthesia, having the potential for improved peripheral vision, and producing less refractive error than laser treatment. On the other hand, it is known that intravitreal administration of anti-VEGF agents lowers VEGF levels in the blood and raises the theoretical concerns of intraocular anti-VEGF causing deleterious effects in other organ systems, including the brain.

Source: Survey of Ophthalmology - March 1, 2021 Category: Opthalmology Authors: Hao Tan, Patricia Blasco, Tamorah Lewis, Susan Ostmo, Michael F Chiang, J. Peter Campbell Source Type: research